A multidisciplinary team of researchers led from Karolinska Institutet in Sweden have developed an anti-inflammatory drug molecule with a new mechanism of action.
By inhibiting a certain protein, the researchers were able to reduce the signals that trigger an inflammation. The study is published in Science and was done in collaboration with the University of Texas Medical Branch, Uppsala University and Stockholm University.
“We’ve developed a new drug molecule that inhibits inflammation,” says Professor Thomas Helleday, at the Department of Oncology-Pathology, Karolinska Institutet, Sweden, who co-led the study with Dr Torkild Visnes and Dr Armando Cázares-Körner. “It acts on a protein that we believe is a general mechanism for how inflammation arises in cells.”
The discovery is the result of many years of research by Thomas Helleday’s group on how DNA is repaired by the body. One of the objectives has been to fight cancer by targeting damage to the tumour cells’ DNA. Several breakthroughs have already been reported, which have led, amongst other things, to a new treatment for congenital breast and ovarian cancer using so-called PARP inhibitors, which has been available for some years.
Trials on mice
It was when developing a new molecule for inhibiting the enzyme that repairs oxygen damage to DNA that the researchers found, to their surprise, that it also dampened inflammation. It turned out that the enzyme OGG1, apart from repairing DNA, also triggers inflammation.
The inhibitor blocks the release of inflammatory proteins, such as TNF alpha. In trials on mice with acute pulmonary disease, the researchers succeeded in dampening the inflammation.
“This discovery could give rise to a new treatment for a very serious condition,” says Professor Helleday. “We’ll now be developing our OGG1 inhibitor and examining whether it can lead to new treatments for inflammatory diseases in order to cure or relieve diseases such as sepsis, COPD and severe asthma.”
The discovery was made in collaboration with Professor Istvan Boldogh from the University of Texas Medical Branch, USA.
The repair pathway on which OGG1 operates was discovered by Tomas Lindahl at Karolinska Institutet in the 1970s, an achievement that earned him the Nobel Prize in Chemistry in 2015.
Collaboration between several universities
The study was a collaboration between Karolinska Institutet, Uppsala University and Stockholm University in Sweden and the University of Texas Medical Branch, USA.
Learn more: New inflammation inhibitor discovered
The Latest on: Anti-inflammatory drug
via Google News
The Latest on: Anti-inflammatory drug
- Can an inexpensive anti-depressant treat COVID-19? Researchers are cautiously optimisticon August 22, 2021 at 7:00 am
Could an anti-depressant called fluvoxamine prevent severe disease of COVID-19 if administered early enough? Scientists are curious enough to keep testing as early results from a clinical trial hold ...
- Anti-inflammatory medication in short supply as COVID-19 drives spike in demandon August 20, 2021 at 6:46 pm
Whether you take Acmetra for arthritis, an auto immune disease, or because you are hospitalized with COVID-19, the drug will soon be difficult to get a hold of.
- Global Anti-Inflammatory Therapeutics Market to Reach $130.9 Billion by 2026on August 20, 2021 at 9:45 am
A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Anti-Inflammatory Therapeutics - Global Market Trajectory & ...
- Anti-Inflammatory Covid-19 Treatment Is in Short Supplyon August 18, 2021 at 2:19 pm
An anti-inflammatory drug used to treat severe cases of Covid-19 is in short supply globally as infections and hospitalizations surge due to the highly transmissible Delta variant. Genentech ...
- Ampio Pharmaceuticals Announces Important New Research Manuscript on Anti-Inflammatory Mode of Actionon August 13, 2021 at 6:15 am
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are ...
- WHO-led trial is studying three anti-inflammatory drugs - used for malaria, leukemia and autoimmune diseases - as potential COVID-19 treatmentson August 12, 2021 at 3:35 pm
A trial led by the World Health Organization is testing three anti-inflammatory drugs - artesunate, imatinib and infliximab- as potential treatments for COVID-19.
- ‘Potential Covid treatments’: WHO mass-testing 3 anti-inflammatory drugson August 11, 2021 at 9:49 pm
WHO announced trials for three potential treatments for Covid-19 patients. WHO chief Dr Tedros Adhanom Ghebreyesus said that clinical trials in 52 countries will study three anti-inflammatory drugs.
- WHO-led trial to study 3 anti-inflammatory drugs as potential treatments for Covid patientson August 11, 2021 at 4:59 pm
These therapies - artesunate, imatinib and infliximab – were selected by an independent expert panel for their potential in reducing the risk of death in hospitalised Covid-19 patients,' WHO said in a ...
- WHO-led trial to study three anti-inflammatory drugs for COVID-19 patientson August 11, 2021 at 7:57 am
The World Health Organization (WHO) said on Wednesday a clinical trial in 52 countries would study three anti-inflammatory drugs as potential treatments for COVID-19 patients.
via Bing News